Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ARTL 
Artelo Biosciences Inc (ARTL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ARTL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $6
1 Year Target Price $6
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.67% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.71M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 2 | Beta 1.03 | 52 Weeks Range 4.92 - 13.27 | Updated Date 06/29/2025 |
52 Weeks Range 4.92 - 13.27 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -17.94 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -89.21% | Return on Equity (TTM) -190.7% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3060868 | Price to Sales(TTM) - |
Enterprise Value 3060868 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.22 | Shares Outstanding 546667 | Shares Floating 542382 |
Shares Outstanding 546667 | Shares Floating 542382 | ||
Percent Insiders 0.81 | Percent Institutions 2.64 |
Analyst Ratings
Rating 2 | Target Price 6 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Artelo Biosciences Inc
Company Overview
History and Background
Artelo Biosciences Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics targeting lipid signaling pathways, including the endocannabinoid system. Founded in 2011, the company has evolved from early-stage research to clinical trials for several drug candidates.
Core Business Areas
- Oncology: Development of therapeutics for cancer, focusing on modulating cancer cell signaling and the tumor microenvironment.
- Pain and Inflammation: Development of treatments for pain and inflammation, targeting the endocannabinoid system to reduce pain signals.
- Neurological Disorders: Exploration of therapeutic applications in neurological disorders, leveraging the endocannabinoid system's role in modulating neuronal activity.
Leadership and Structure
Gregory D. Gorgas serves as the Chief Executive Officer. The company has a structured management team overseeing research, clinical development, and operations.
Top Products and Market Share
Key Offerings
- ART27.13: ART27.13 is a G protein-coupled receptor (GPCR) modulator being developed for cancer anorexia. It is currently in clinical trials. No specific market share data is yet available as it is still in development. Competitors include pharmaceutical companies developing treatments for cancer-related cachexia.
- ART12.11: ART12.11 is a co-crystal inhibitor being developed for inflammatory bowel disease (IBD). It is currently in pre-clinical stage. No specific market share data is yet available as it is still in development. Competitors include pharmaceutical companies developing treatments for IBD such as Crohn's disease and ulcerative colitis.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high R&D costs, and stringent regulatory requirements. Companies focus on developing innovative therapies for unmet medical needs.
Positioning
Artelo Biosciences Inc. is a clinical-stage company focusing on lipid signaling pathways. It positions itself as an innovator in endocannabinoid system-targeted therapies.
Total Addressable Market (TAM)
The total addressable market for cancer anorexia and IBD treatments is significant, potentially reaching billions of dollars annually. Artelo is positioned to capture a portion of this market with successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Novel therapeutic targets in the endocannabinoid system
- Clinical-stage drug candidates
- Experienced management team
Weaknesses
- Limited financial resources
- High dependence on clinical trial success
- Small company size compared to competitors
Opportunities
- Potential for partnerships and collaborations
- Expanding applications of endocannabinoid-targeted therapies
- Favorable regulatory environment for innovative therapies
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- GWPH
- CRBP
- ABBV
Competitive Landscape
Artelo Biosciences Inc. faces competition from larger, more established pharmaceutical companies. Its competitive advantage lies in its focus on lipid signaling pathways and its novel therapeutic candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by preclinical and clinical development milestones.
Future Projections: Future growth is contingent on the successful development and commercialization of its drug candidates. Analyst projections are not readily available in a structured format.
Recent Initiatives: Recent initiatives include advancing ART27.13 and ART12.11 through clinical trials and exploring new therapeutic applications.
Summary
Artelo Biosciences Inc. is a high-risk, high-reward clinical-stage biopharmaceutical company with promising drug candidates targeting the endocannabinoid system. Its success hinges on positive clinical trial outcomes and the ability to secure funding. The company needs to carefully manage its cash resources and compete effectively with larger companies in the space.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Financial databases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Artelo Biosciences Inc
Exchange NASDAQ | Headquaters Solana Beach, CA, United States | ||
IPO Launch date 2017-11-14 | President, CEO, CFO, Treasurer, Secretary & Director Mr. Gregory D. Gorgas M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.artelobio.com |
Full time employees 5 | Website https://www.artelobio.com | ||
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated/ weight loss with cancer; and ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, pain and inflammation, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.